Efficacy of Methylprednisolone Pulses in Neuroendocrine Celles Hyperplasia of Infancy : An Early Phase Study

Overview

Childhood interstitial lung diseases (chILD) are a heterogeneous group of rare and severe disorders with an estimated prevalence of 1/100,000. Among them, neuroendocrine cells hyperplasia of infancy (NEHI), also called persistent tachypnoea of infancy (PTI), is one of the most common aetiology (up to 16% of the cases). NEHI involves young infants (median age at onset 3 to 6 months) with tachypnoea, hypoxemia, crackles, retractions, failure to thrive and specific localizations of ground glass opacities (GGO) on chest CT-scan (paramediastinal areas and anterior lobes (right middle lobe and lingula). At diagnosis, most patients (50 to 100%) require oxygen supplementation that usually lasts for months to years, sometimes associated with nutritional support with eventual enteral nutrition. NEHI is believed to be related to an increased number of neuroendocrine cells in airway epithelial area. These cells are abundant in foetal life, when they play a role in regulating the lung development and decrease before birth. There is no specific treatment for NEHI. The main treatment of chILD is corticosteroids. However, in NEHI, their efficacy is matter of debate. There is only a few NEHI cases series or cohorts all over the world, accounting for a maximum of 500 reported cases within only retrospective studies. Among them, United States and Argentina teams report supportive care only (oxygen therapy and nutritional support) whereas other teams, like the French ones largely uses IV corticosteroid pulses. Unlike the majority of chILD, NEHI prognosis is usually good. However, at school-age, 26% of the patients remain symptomatic or have an abnormal lung function. Moreover, oxygen therapy significantly affects quality of life (QoL) of the children with ILD (-10.43/100 points, p=0.02) but also QoL and mood of their parents (unpublished data). The present study hypothesis that corticosteroids are associated with a reduction of the length of oxygen support in infants with NEHI.

Detailed description

This study aims at assessing the beneficial effect of IV methylprednisolone pulses on oxygen therapy in infants with NEHI. It applies to all hypoxic NEHI patients aged below 12 months and followed in one of the centres of the RespiRare network. 18 patients will be recruited.

CORTICO-NEHI is designed as an early phase study following an A'Hern's Single Stage Phase II design.

All the patients are included in a single group receiving as a standard of care a maximum of 6 IV pulses of 3 days each.

12 visits will be performed as a standard of care:

* Screening visit (M-1 at maximum) :follow-up routine visit, (usually the hospitalization for NEHI diagnosis). If the patient is eligible, parents are informed of the study and an informed note is given. Information on the study protocol is given to obtain their written consent as soon as possible, and at the latest at the inclusion. * Inclusion (M0) : After checking of the inclusion criteria and the absence of exclusion criteria, information and collection of parental consent. Following these investigations, the patient's first IV methylprednisolone pulse (D1) is administrated within the limit of 10 days. * Treatment visits (M0 - M5): During a hospitalization, 6 pulses are performed at a 4 weeks interval (+/- 10 days). Each pulse is a 3-days-6h-perfusions of Methylprednisolone (500mg and 120mg) 10mg/kg/day diluted in 50ml of saline under supervision of SpO2, heart rate, blood pressure / 30min. If oxygen can be stopped (2 oxymetries with a 1-week interval +/- 10 days): The endpoint is reached and the methylprednisolone pulses are definitively stopped. * Follow-up visits (M6, M9, M12, M15 and M18)

For the research needs,

* CT scan and Echocardiography will be done at inclusion if not performed in the past 3 months * QoL questionnaires will be performed at inclusion, M6, M12 and M18 * Dipstick for sugar will be performed at M6, M9, M12, M15, M18 (in addition to M0 - M5 according to the standard of care)

Interventions

• Drug IV Methylprednisolone pulses
  Six (6) pulses (max) are performed at a 4 weeks interval (+/- 10 days). Each pulse is a 3-days-6h-perfusions of Methylprednisolone (500mg and 120mg) 10mg/kg/day diluted in 50ml of saline under supervision of SpO2, heart rate, blood pressure /

Primary outcome measures

• Number of children still requiring oxygen therapy [Time frame: Month 18]

Secondary outcome measures (12)

• Time to achieve the oxygen therapy weaning [Time frame: Month 18]
• The number of patients requiring continuous oxygen therapy (meaning sleep and awake oxygen therapy by opposition to sleep oxygen only) over time [Time frame: Month 18]
• The number of patients requiring only sleep oxygen over time [Time frame: Month 18]
• The number of patients with a normal respiratory rate [Time frame: Month 18]
• ChILD healing (reduction of severity) over time [Time frame: Between Month 0 and Month 18]
• Parents QoL [Time frame: Month 0 and Month 18]
• Patient's QoL [Time frame: Month 0 and Month 18]
• Impact of NEHI on feeding and growth status [Time frame: Between Month 0 and Month 18]
• Safety of methylprednisolone pulses [Time frame: Between Month 0 and Month 18]
• Number of antibiotic courses for an infectious lung exacerbation [Time frame: Between Month 0 and Month 18]
• Safety of methylprednisolone pulses [Time frame: At Month 6]
• Safety of methylprednisolone pulses [Time frame: At Month 6]

Eligibility criteria

Inclusion criteria

• Infant aged under 12 months
• NEHI diagnosis based on:

• The recently validated clinical Liptzin score ≥7/10 associated with a suggestive thoracic CT pattern with ground glass opacities confined to middle lobe, lingula, and paramediastinal lung areas OR
• a clinical and thoracic CT suspicion and a lung biopsy showing an increased number of neuroendocrine cells in the epithelial airways area (at least one bronchiole with at least 10% of neuroendocrine cells)
• Oxygen requirement (awake and/or asleep) based on the usual pediatric recommendations (see section 4.1.1)
• Followed in one of the RespiRare participating centers
• Written informed consent of the holder(s) of its legal representative at the inclusion

Exclusion criteria

• Other cause of chILD assessed by lab biology tests, genetic analysis for surfactant genes (if available), bronchoalveolar lavage, and/or lung biopsy.
• Patient treated with IV methylprednisolone pulses before (any time)
• Diabetes
• Uncontrolled arterial hypertension
• Absence of Health care insurance
• Ongoing infection
• Immunization with a live attenuated vaccine within the past two weeks
• Long term treatment with Azithromycin and/or Hydroxychloroquine
• Patients already included in an interventional study (RIPH1, clinical investigation or clinical trial)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

France · 1 center

• Pediatric Pulmonology Department and Reference centre for rare lung diseases — Paris

Identifiers

NCT: NCT06471556 · APHP230821 · 2023-508132-65-00

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗